about
Understanding DNA under oxidative stress and sensitization: the role of molecular modelingCytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer DrugKinetic and mechanistic studies on reactions of diruthenium(II,III) with biologically relevant reducing agents.DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes.Cytotoxicity of Pyrazine-Based Cyclometalated (C^Npz^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties.1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity.Encapsulation of pyrene-functionalized poly(benzyl ether) dendrons into a water-soluble organometallic cage.Excellent correlation between drug release and portal size in metalla-cage drug-delivery systems.Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.Ruthenium(II) arene complexes with chelating chloroquine analogue ligands: synthesis, characterization and in vitro antimalarial activity.Preparation of organometallic ruthenium-arene-diaminotriazine complexes as binding agents to DNA.Interaction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products.Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C(∧)N-Chelated and Pyridine Ligands.Novel C,N-chelate rhodium(III) and iridium(III) antitumor complexes incorporating a lipophilic steroidal conjugate and their interaction with DNA.Organometallic anticancer compoundsNew ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity.Anticancer Activity of Self-Assembled Molecular Rectangles via Arene-Ruthenium Acceptors and a New Unsymmetrical Amide LigandMir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancerFighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies.Targeted and multifunctional arene ruthenium chemotherapeutics.Dicarba-closo-dodecarborane-containing half-sandwich complexes of ruthenium, osmium, rhodium and iridium: biological relevance and synthetic strategies.Organometallic compounds: an opportunity for chemical biology?Novel lead structures and activation mechanisms for CO-releasing molecules (CORMs)Metallomics insights into the programmed cell death induced by metal-based anticancer compounds.Antiproliferative activity of (η(6)-arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines.Half-Sandwich Ru(II) Halogenido, Valproato and 4-Phenylbutyrato Complexes Containing 2,2'-Dipyridylamine: Synthesis, Characterization, Solution Chemistry and In Vitro Cytotoxicity.Platinum(ii) O,S complexes as potential metallodrugs against Cisplatin resistance.Combining a Ru(ii)-arene complex with a NO-releasing nitrate-ester ligand generates cytotoxic activity.Insights into the in vitro Anticancer Effects of Diruthenium-1.Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.The contrasting catalytic efficiency and cancer cell antiproliferative activity of stereoselective organoruthenium transfer hydrogenation catalysts.Chlorambucil conjugates of dinuclear p-cymene ruthenium trithiolato complexes: synthesis, characterization and cytotoxicity study in vitro and in vivo.Heteroleptic arene Ru(II) dipyrrinato complexes: DNA, protein binding and anti-cancer activity against the ACHN cancer cell line.Investigations on dendrimer space reveal solid and liquid tumor growth-inhibition by original phosphorus-based dendrimers and the corresponding monomers and dendrons with ethacrynic acid motifs.Combining [arene-Ru] with azocarboxamide to generate a complex with cytotoxic properties.Precious metal carborane polymer nanoparticles: characterisation of micellar formulations and anticancer activity.Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo.Anticancer potency studies of coordination driven self-assembled arene–Ru-based metalla-bowls.A deadly organometallic luminescent probe: anticancer activity of a ReI bisquinoline complex.
P2860
Q26799860-EF2CE3F3-77BA-42A8-966F-2D9BB23716A6Q27702884-F8210FF9-3B13-475A-A4A4-120A34E5F125Q28547627-DC3AC3D1-5703-4987-90B1-3E9A636D2335Q30670864-1B79ED85-BAD9-4C54-8158-A2CFCCCDFB0DQ31043552-5B42AB9D-A34E-4FD9-A58B-E87C420FD5F2Q33696556-3A84A7EF-3427-4F60-818E-38A97B8D0822Q33862825-F7DD29FB-7F25-4082-84BE-A758EFA0C39EQ33917124-EB72FF8B-626A-44A2-9DFF-9C95AA679B25Q33953543-97FFAA6B-9639-49B2-8D36-EE85AE5AB16AQ33991566-EDF725AF-611C-44FE-8615-D767B46C313EQ34128946-554D7C46-09C2-4086-8998-8810697B1276Q34151556-B2D1FC91-159F-48F3-BE8F-6779320B1DC6Q34327703-67E947A6-6252-467E-9973-C1D66D60637DQ34331245-8D3F4596-306A-4D1F-8B7D-804C4404565DQ34415646-8262A29E-2EDC-4AEB-A6BB-452813248928Q34476685-C83F8867-077B-4E02-B7C2-BFA24E0B2186Q35029887-F7227AFE-1DF1-47AB-B14E-F1A8B07F075CQ35983960-2AC57E6F-31BA-4B2B-BA6A-E7B220396395Q36853421-E62779D0-03D9-47A1-ADB4-8CDBC1D15A41Q37337277-67D20B1B-EAE9-49D3-82F5-5C66520AF64FQ37920741-4480BE11-0D85-479A-AACE-FA8A8AAF0D20Q37981543-E014CDE6-F4F3-432E-9110-E626D1743E00Q38012429-CE30796B-DBD3-4255-ADAE-4E5F1DA3B2FAQ38195891-62F1B6B9-DC22-4C8A-97B0-832DD2E42B60Q38199383-877CCA81-2878-4266-938E-5B044A344E3EQ38695135-0F826470-C39A-4505-A880-DE152792DA3CQ38725899-91F1E34D-DA22-40BC-B4E4-774BCB764FE6Q38728438-9620719C-48E0-4BB4-8889-9134461612E5Q38734166-97D1E3B9-DAE3-4FAB-8045-571ADE7679A1Q38750151-9C9FC9B1-5FCC-4C64-A3A1-93AD96CDDC23Q38770155-35AB20A1-91FE-4155-9DD5-76E82B8A2254Q38775808-615FA7A3-20FB-4B51-9683-31847661E2A2Q38781054-4C300B83-7FE7-4143-AF6D-5A0E79C1DB46Q38783737-BF3BC3EF-0706-49B2-8EE3-7FF65AAA1A36Q38928796-62C9302C-49B0-4CB4-81F9-410D7DA70B9FQ38942212-E08DA401-7D59-495F-89C6-2A5D22057BD5Q38951818-1CE2061E-18C6-45EE-8890-FCABBD98A002Q38995385-38B86E36-D2F9-444F-991A-B1DFC6255E19Q39010752-12452815-AF50-458F-868B-3F25DBF99F53Q39030454-E00B896C-DF07-4904-B7B0-DC334EB733CB
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Arene ruthenium complexes as anticancer agents.
@en
Arene ruthenium complexes as anticancer agents.
@nl
type
label
Arene ruthenium complexes as anticancer agents.
@en
Arene ruthenium complexes as anticancer agents.
@nl
prefLabel
Arene ruthenium complexes as anticancer agents.
@en
Arene ruthenium complexes as anticancer agents.
@nl
P2860
P356
P1433
P1476
Arene ruthenium complexes as anticancer agents.
@en
P2093
Georg Süss-Fink
P2860
P304
P356
10.1039/B916860P
P407
P577
2009-10-23T00:00:00Z